EGRX Eagle Pharmaceuticals Inc.

61.99
+1.26  (+2%)
Previous Close 60.73
Open 60.99
Price To Book 4.91
Market Cap 847,209,891
Shares 13,666,880
Volume 144,840
Short Ratio
Av. Daily Volume 157,089
Stock charts supplied by TradingView

NewsSee all news

  1. Eagle Pharmaceuticals' Japanese Licensing Partner SymBio Announces its Submission of a New Drug Application for TREAKISYM® Ready-To-Dilute Formulation

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited ("SymBio") has submitted a New Drug Application ("NDA") for TREAKISYM

  2. Eagle Pharmaceuticals, Inc. to Present at 2019 Cantor Global Healthcare Conference

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2019 Cantor Global

  3. Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Morgan Stanley 17th Annual

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Pilot trial planned, to be followed by pivotal trial.
Fulvestrant
Breast cancer
Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.
PEMFEXY,
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. Additional trial required.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Ryanodex
Malignant hyperthermia - cancer
Intends to meet with FDA June 2019 to discuss path forward.
Ryanodex
Exertional heat stroke (EHS)
Data released May 7, 2019 noted lower incidence of brain damage.
Ryanodex
Nerve agent (NA) exposure

Latest News

  1. Eagle Pharmaceuticals' Japanese Licensing Partner SymBio Announces its Submission of a New Drug Application for TREAKISYM® Ready-To-Dilute Formulation

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited ("SymBio") has submitted a New Drug Application ("NDA") for TREAKISYM

  2. Eagle Pharmaceuticals, Inc. to Present at 2019 Cantor Global Healthcare Conference

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2019 Cantor Global

  3. Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Morgan Stanley 17th Annual